B-intervention	0	16	Polychemotherapy
O	17	20	for
O	21	26	early
O	27	33	breast
O	34	40	cancer
O	40	41	:
O	42	49	results
O	50	54	from
O	55	58	the
O	59	72	international
O	73	81	adjuvant
O	82	88	breast
O	89	95	cancer
O	96	108	chemotherapy
O	109	119	randomized
O	120	125	trial
O	125	126	.

O	127	135	Survival
O	136	138	of
O	139	147	patients
O	148	152	with
O	153	158	early
O	158	159	-
O	159	164	stage
O	165	171	breast
O	172	178	cancer
O	179	181	is
O	182	190	improved
O	191	200	following
O	201	210	treatment
O	211	215	with
O	216	222	single
O	222	223	-
O	223	231	modality
O	232	241	tamoxifen
O	241	242	,
O	243	250	ovarian
O	251	259	ablation
O	260	262	or
O	263	274	suppression
O	274	275	,
O	276	278	or
O	279	291	chemotherapy
O	291	292	.

O	293	296	The
O	297	305	Adjuvant
O	306	312	Breast
O	313	319	Cancer
O	320	326	Trials
O	327	331	were
O	332	340	designed
O	341	343	to
O	344	353	ascertain
O	354	357	any
O	358	368	additional
O	369	377	benefits
O	378	380	of
O	381	389	combined
O	390	399	treatment
O	399	400	.

O	401	404	The
O	405	413	Adjuvant
O	414	420	Breast
O	421	427	Cancer
O	428	440	Chemotherapy
O	441	446	Trial
O	447	450	was
O	451	452	a
O	453	463	randomized
O	464	469	phase
O	470	473	III
O	474	479	trial
O	480	482	in
O	483	488	which
B-eligibility	489	497	patients
I-eligibility	498	502	with
I-eligibility	503	508	early
I-eligibility	508	509	-
I-eligibility	509	514	stage
I-eligibility	515	521	breast
I-eligibility	522	528	cancer
I-eligibility	529	532	who
I-eligibility	533	537	were
I-eligibility	538	547	receiving
I-eligibility	548	557	prolonged
I-eligibility	558	559	(
I-eligibility	559	560	5
I-eligibility	561	566	years
I-eligibility	566	567	)
I-eligibility	568	577	tamoxifen
I-eligibility	578	587	treatment
I-eligibility	587	588	,
I-eligibility	589	593	with
I-eligibility	594	596	or
I-eligibility	597	604	without
I-eligibility	605	612	ovarian
I-eligibility	613	621	ablation
I-eligibility	622	624	or
I-eligibility	625	636	suppression
O	636	637	,
O	638	642	were
O	643	651	randomly
O	652	660	assigned
O	661	663	to
O	664	672	standard
O	673	685	chemotherapy
O	686	692	versus
B-control	693	697	none
O	697	698	.

O	699	704	Trial
O	705	714	endpoints
O	715	723	included
B-outcome-Measure	724	731	relapse
I-outcome-Measure	731	732	-
I-outcome-Measure	732	736	free
O	737	740	and
B-outcome-Measure	741	748	overall
I-outcome-Measure	749	757	survival
O	757	758	.

O	759	765	Hazard
O	766	772	ratios
O	773	774	(
O	774	777	HRs
O	777	778	)
O	779	783	were
O	784	791	derived
O	792	796	from
O	797	800	Cox
O	801	807	models
O	807	808	,
O	809	812	and
O	813	816	all
O	817	828	statistical
O	829	834	tests
O	835	839	were
O	840	843	two
O	843	844	-
O	844	849	sided
O	849	850	.

O	851	858	Between
O	859	863	1992
O	864	867	and
O	868	872	2000
O	872	873	,
B-total-participants	874	878	1991
O	879	887	patients
B-age	888	895	between
I-age	896	899	the
I-age	900	904	ages
I-age	905	907	of
I-age	908	910	26
I-age	911	914	and
I-age	915	917	81
I-age	918	923	years
O	924	928	were
O	929	937	randomly
O	938	946	assigned
O	947	948	(
B-intervention-participants	948	951	987
O	952	954	to
O	955	967	chemotherapy
O	967	968	,
B-control-participants	969	973	1004
O	974	976	to
O	977	979	no
O	980	992	chemotherapy
O	992	993	)
O	994	998	from
O	999	1002	106
B-location	1003	1005	UK
O	1006	1009	and
O	1010	1012	16
B-location	1013	1016	non
I-location	1016	1017	-
I-location	1017	1019	UK
O	1020	1027	centers
O	1027	1028	.

B-intervention-participants	1029	1033	Nine
I-intervention-participants	1034	1041	hundred
I-intervention-participants	1042	1047	seven
O	1048	1049	(
O	1049	1051	92
O	1051	1052	%
O	1052	1053	)
O	1054	1062	patients
O	1063	1071	received
O	1072	1084	chemotherapy
O	1085	1087	as
O	1088	1097	allocated
O	1098	1099	(
O	1099	1101	87
O	1101	1102	%
O	1103	1111	received
O	1112	1128	cyclophosphamide
O	1128	1129	,
O	1130	1142	methotrexate
O	1142	1143	,
O	1144	1147	and
O	1148	1149	5
O	1149	1150	-
O	1150	1162	fluorouracil
O	1162	1163	;
O	1164	1166	11
O	1166	1167	%
O	1168	1176	received
O	1177	1190	anthracycline
O	1190	1191	-
O	1191	1201	containing
O	1202	1210	regimens
O	1210	1211	)
O	1211	1212	.

O	1213	1214	A
O	1215	1220	total
O	1221	1223	of
O	1224	1227	244
O	1228	1230	of
O	1231	1234	the
O	1235	1238	619
O	1239	1252	premenopausal
O	1253	1261	patients
O	1262	1270	received
O	1271	1279	elective
O	1280	1287	ovarian
O	1288	1296	ablation
O	1297	1299	or
O	1300	1311	suppression
O	1311	1312	.

O	1313	1325	Chemotherapy
O	1326	1334	improved
B-outcome	1335	1342	relapse
I-outcome	1342	1343	-
I-outcome	1343	1347	free
I-outcome	1348	1356	survival
O	1357	1358	(
O	1358	1365	relapse
O	1366	1368	in
O	1369	1372	the
O	1373	1385	chemotherapy
O	1386	1391	group
O	1392	1398	versus
O	1399	1401	no
O	1401	1402	-
O	1402	1414	chemotherapy
O	1415	1420	group
O	1420	1421	,
B-iv-bin-abs	1422	1425	298
O	1426	1432	events
O	1433	1439	versus
B-cv-bin-abs	1440	1443	332
O	1444	1450	events
O	1450	1451	,
O	1452	1454	HR
O	1455	1456	=
O	1457	1458	0
O	1458	1459	.
O	1459	1461	86
O	1461	1462	,
O	1463	1465	95
O	1465	1466	%
O	1467	1477	confidence
O	1478	1486	interval
O	1487	1488	[
O	1488	1490	CI
O	1490	1491	]
O	1492	1493	=
O	1494	1495	0
O	1495	1496	.
O	1496	1498	73
O	1499	1501	to
O	1502	1503	1
O	1503	1504	.
O	1504	1506	01
O	1506	1507	;
O	1508	1509	P
O	1510	1511	=
O	1512	1513	.
O	1513	1515	06
O	1515	1516	)
O	1517	1520	and
B-outcome	1521	1528	overall
I-outcome	1529	1537	survival
O	1538	1539	(
O	1539	1544	death
O	1545	1549	from
O	1550	1553	any
O	1554	1559	cause
O	1560	1562	in
O	1563	1566	the
O	1567	1579	chemotherapy
O	1580	1585	group
O	1586	1592	versus
O	1593	1595	no
O	1595	1596	-
O	1596	1608	chemotherapy
O	1609	1614	group
O	1614	1615	,
B-iv-bin-abs	1616	1619	243
O	1620	1626	events
O	1627	1633	versus
B-cv-bin-abs	1634	1637	282
O	1638	1644	events
O	1644	1645	,
O	1646	1648	HR
O	1649	1650	=
O	1651	1652	0
O	1652	1653	.
O	1653	1655	83
O	1655	1656	,
O	1657	1659	95
O	1659	1660	%
O	1661	1663	CI
O	1664	1665	=
O	1666	1667	0
O	1667	1668	.
O	1668	1670	70
O	1671	1673	to
O	1674	1675	0
O	1675	1676	.
O	1676	1678	99
O	1678	1679	;
O	1680	1681	P
O	1682	1683	=
O	1684	1685	.
O	1685	1687	03
O	1687	1688	)
O	1689	1694	after
O	1695	1705	adjustment
O	1706	1709	for
O	1710	1715	nodal
O	1716	1722	status
O	1722	1723	,
O	1724	1732	estrogen
O	1733	1741	receptor
O	1742	1748	status
O	1748	1749	,
O	1750	1753	and
O	1754	1757	age
O	1757	1758	.

O	1759	1767	Subgroup
O	1768	1776	analyses
O	1777	1783	showed
O	1784	1788	that
O	1789	1792	the
O	1793	1800	benefit
O	1801	1803	of
O	1804	1816	chemotherapy
O	1817	1820	was
O	1821	1829	greatest
O	1830	1832	in
O	1833	1840	younger
O	1841	1846	women
O	1847	1848	(
O	1848	1849	<
O	1849	1851	50
O	1852	1857	years
O	1857	1858	)
O	1859	1862	and
O	1863	1865	in
O	1866	1876	particular
O	1877	1880	for
O	1881	1894	premenopausal
O	1895	1900	women
O	1901	1904	not
O	1905	1914	receiving
O	1915	1922	ovarian
O	1923	1931	ablation
O	1932	1934	or
O	1935	1946	suppression
O	1946	1947	.

O	1948	1954	Modest
O	1955	1958	yet
O	1959	1970	sustainable
O	1971	1979	benefits
O	1980	1983	for
O	1984	1998	chemoendocrine
O	1999	2006	therapy
O	2007	2012	occur
O	2013	2015	in
O	2016	2021	women
O	2022	2026	with
O	2027	2033	breast
O	2034	2040	cancer
O	2040	2041	.

O	2042	2049	However
O	2049	2050	,
O	2051	2054	the
O	2055	2059	full
O	2060	2066	impact
O	2067	2069	on
O	2070	2077	overall
O	2078	2086	survival
O	2087	2090	may
O	2091	2094	not
O	2095	2101	emerge
O	2102	2105	for
O	2106	2113	several
O	2114	2119	years
O	2119	2120	.
